Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Dihon

- PMLiVE

Chi-Med cues up two more regulatory filings in cancer

Hong Kong based firm reports strong sales in first marketed product

- PMLiVE

CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

GW Pharma’s Epidyolex also on the recommended list

- PMLiVE

Hansoh Pharma shares head skyward after HKEX debut

Adds to China's growing presence in life sciences

- PMLiVE

Swedish biotech Calliditas signs China licensing deal for autoimmune candidate

IgA nephropathy more common in China

- PMLiVE

Chi-Med goes for third IPO in Hong Kong

New listing follows first product launch

Live Webinar: China in the fast lane: How to play and win in the world’s hottest emerging market

Tuesday 16th April 2019 10:00 EST/ 15:00 GMT / 16:00 CEST

Research Partnership

Novartis day

Novartis claims first place for psoriasis drug Cosentyx in China

Trial data from China helped support filing

- PMLiVE

Innovent gears up for PD-1 inhibitor launch in China

Analysts say the approval marks a move away from developing ‘me-too’ drugs

Bayer symbol

Bayer, Orion prep challenge in prostate cancer market

New arrival will face tough competition, not least generic Zytiga

- PMLiVE

Cancer drugs and China sustain AZ’s return to growth

Tagrisso set to become biggest seller

- PMLiVE

Rising economic risk casts shadow on Davos meeting

Slowing growth in key economies causing concern

China’s clinical trial shake-up

As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links